In the Unlock the Editor’s Digest, Roula Khalaf selects key stories, including the US economy adding 254,000 jobs in September, leading to speculation of a slower pace of interest rate cuts by the Federal Reserve. The strong job market is seen as positive for Vice President Kamala Harris’s presidential bid, with economists praising the robust growth and employment. Despite the positive data, concerns remain about potential recession fears and the impact on interest rate policies moving forward.
Full Article
3 Magnificent Stocks That Could Double or More by 2030
In a turbulent stock market, three Motley Fool contributors recommend investing in CRISPR Therapeutics, Summit Therapeutics, and Viking Therapeutics, which they believe could see significant gains by 2030. CRISPR Therapeutics, despite recent struggles, has a promising gene-editing therapy, Casgevy, and a robust pipeline. Summit Therapeutics is poised to challenge established drugs with its ivonescimab, while Viking Therapeutics offers potential through its GLP-1 drug, VK2735, with ongoing clinical trials targeting obesity and metabolic disorders. Full Article
Read more